I found this info on Qrx Pharmaceutical's website. Don't know actually what this could mean to AXN?
Following surgery, many patients are not able to ingest oral medication and instead receive morphine intravenously. Q8012, an intravenous (IV) Dual Opioid formulation of morphine and oxycodone in a fixed 1:2 ratio, is being developed as first line therapy for acute moderate to severe hospital-based pain. The Dual Opioid IV formulation has completed a proof-of-concept Phase 2 trial.
QRxPharma and Aoxing Pharmaceutical Company (NYSE AMEX:AXN) established a strategic alliance for the development of Q8012 for the Chinese marketplace."